Novartis Pharma AG: Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I|III clinical trial
ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postme…
Novartis Pharma AG: Sandoz announces further progress on its biosimilar pipeline, with release of positive results for denosumab integrated Phase I|III clinical trial
ROSALIA study met primary endpoints, confirming proposed biosimilar denosumab matches reference product in terms of pharmacokinetics, pharmacodynamics, efficacy, safety and immunogenicity in postme…